Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest blood clots Stories

2012-09-14 23:01:07

The NuvaRing Resource Center is the Web´s largest source for information on NuvaRing side effects, research and legal news. Visit http://www.NuvaRing-Lawsuits.net Orlando, FL (PRWEB) September 14, 2012 The NuvaRing Resource Center, a patient advocacy group, is alerting those women who used NuvaRing contraceptive devices that experts have related the vaginal rings to increased risks of blood clots. Also, a federal judge recently ordered trials will start soon for those who have filed an...

2012-09-07 02:23:57

RARITAN, N.J., Sept. 7, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that it has submitted the Complete Response to the U.S. Food and Drug Administration (FDA) for the use of XARELTO(®) (rivaroxaban) to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS). The response includes specific information requested by the FDA in their letter issued to Janssen on June 21, 2012. Janssen also has resubmitted the...

Microvisk-6_L
2012-08-16 21:39:55

Lee Rannals for redOrbit.com - Your Universe Online Patients being medicated for blood clots may soon have tiny robot space bugs to thank for one day getting a simple, home-use testing kit. Vladislav Djakov started building micro-electromechanical creatures 15 years ago that mimic the swarms of bugs found in nature. The bugs were equipped with a power supply, limited intelligence and monitoring systems, and were put in hard-to-reach places on the International Space Station. They...

2012-07-20 23:00:49

HealthyAnswers.com is a publisher and a leader in providing current natural health information on their website. Along with thousands of archived articles on health related issues, they also offer a complimentary health newsletter, quality nutritional solutions, and self improvement books. HealthyAnswers.com warns of summer travel and the development of blood clots. Delray Beach, FL (PRWEB) July 20, 2012 In a recent newsletter article, HealthyAnswers.com related the danger of developing...

2012-07-09 02:24:47

RARITAN, N.J., July 9, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO(®) (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE. DVT is a condition in...

2012-06-25 21:07:35

Many patients with type 2 diabetes may be aspirin resistant. That means the standard aspirin dose may not protect them against blood clots that cause heart attacks and strokes among diabetics, a new clinical study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston. "This result adds to our understanding of the prevalence of this problem, which varies considerably among studies," said lead author Subhashini Yaturu, M.D., section chief of...

2012-06-21 14:21:59

RARITAN, N.J., June 21, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO(®) (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS). Janssen is evaluating the complete response letter and will respond to the agency's questions....

2012-05-23 10:26:08

RARITAN, N.J., May 23, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted against the approval of XARELTO(®) (rivaroxaban), an oral anticoagulant, to reduce the risk of secondary cardiovascular events in patients with Acute Coronary Syndrome (ACS) in combination with standard antiplatelet therapy. "We appreciate the thoroughness of the...

2012-05-17 23:01:49

According to the study published on May 10th 2012 in the British Medical Journal, non-oral contraceptives, including NuvaRing, have a higher risk of blood clots than combined oral contraceptives (COCs) based on oestrogens and progestins. NuvaRing, approved by the FDA in 2001, is a contraceptive that comes in the form of a vaginal ring using female hormones in an effort to prevent ovulation. Women who used a vaginal ring had a 6.5 times higher risk for developing blood clots compared to...

2012-05-09 02:27:35

RARITAN, N.J., May 9, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO(®) (rivaroxaban), an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome (ACS). XARELTO(® )currently is under review with the U.S. FDA to reduce the risk of secondary...